| Revision as of 19:47, 13 January 2011 editEdgar181 (talk | contribs)Extended confirmed users196,325 editsm moved SCH-530,348 to Vorapaxar: current generic drug name← Previous edit |
Revision as of 19:54, 13 January 2011 edit undoEdgar181 (talk | contribs)Extended confirmed users196,325 edits recent newsNext edit → |
| Line 1: |
Line 1: |
|
{{Orphan|date=February 2009}} |
|
|
{{Drugbox |
|
{{Drugbox |
|
| IUPAC_name = Ethyl ''N''-vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3''H''-benzoisobenzofuran-7-yl]carbamate |
|
| IUPAC_name = Ethyl ''N''-vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3''H''-benzoisobenzofuran-7-yl]carbamate |
|
|
| synonyms = SCH-530348 |
|
| image = SCH-530348.png |
|
| image = SCH-530348.png |
|
| CAS_number = 618385-01-6 |
|
| CAS_number = 618385-01-6 |
| Line 26: |
Line 26: |
|
}} |
|
}} |
|
|
|
|
|
'''SCH-530,348''' is a ] receptor (]) antagonist based on the natural product ]. Developed by ], SCH-530,348 is a potential treatment for acute coronary syndrome chest pain caused by coronary artery disease.<ref name=chack>{{cite journal|author= Samuel Chackalamannil|title=Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity|journal=]|year=2008|doi =10.1021/jm800180e|volume= 51|pages= 3061}}</ref> |
|
'''Vorapaxar''' (formerly SCH-530,348) is a ] receptor (]) antagonist based on the natural product ]. Discovered by ] and currently being developed by ], it is a experimental pharmaceutical treatment for acute coronary syndrome chest pain caused by coronary artery disease.<ref name=chack>{{cite journal|author= Samuel Chackalamannil|title=Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity|journal=]|year=2008|doi =10.1021/jm800180e|volume= 51|pages= 3061}}</ref> |
|
|
|
|
|
|
In January 2010, clinical trials being conducted by Merck were halted for patients with stroke and mild heart conditions.<ref>, '']'', January 13, 2010</ref> Merck is uncertain whether further development of vorapaxar will continue. |
|
Now owned by Merck, this compound is being called Vorapaxar. |
|
|
|
|
|
|
==References== |
|
==References== |
In January 2010, clinical trials being conducted by Merck were halted for patients with stroke and mild heart conditions. Merck is uncertain whether further development of vorapaxar will continue.
